** Shares of drug developer Lipocine up 6.19% at $5.5 in premarket trading

** Administration of Oral brexanolone, co's drug for treating post-partum depression, was consistent with therapies effective in managing depression, anxiety, tremors, and seizures

**Oral brexanolone was well-tolerated in the Phase 1 study, with a safety profile consistent with previous clinical studies

** As of last close stock up 85.30% YTD

(Reporting by Khusbu Jena)

((Khusbu.Jena@thomsonreuters.com;))